|Systematic (IUPAC) name|
(5Z,9α,11α,13E,15S)-9,11,15-trihydroxy-15- methylprosta-5,13-dien-1-oic acid
|CAS Registry Number|
|Molecular mass||368.508 g/mol|
|(what is this?)|
Used in postpartum hemorrhage caused by uterine atony not controlled by other methods. One study has shown that carboprost tromethamine is more effective than oxytocin in preventing postpartum hemorrhage in high-risk patients undergoing caesarian delivery. Carboprost is also used for the termination of pregnancy in the 2nd trimester.
- Hemorrhagic Cystitis
Contraindicated in severe cardiovascular, renal, and hepatic disease. It is also contraindicated in acute Pelvic Inflammatory Disease. Hypersensitivity to carboprost or any of its components is also a contraindication Exert caution in asthmatic patients.
- diabetes mellitus
- seizure disorders
- past uterine surgery
- diarrhea (most common, may be sudden in onset)
- flushing or hot flashes
Storage and Availability
Carboprost is supplied with its salt derivative tromethamine in 1 milliliter ampules containing a 250 microgram/milliliter solution of the active drug. The drug must be refrigerated at a temperature between 2 – 8 degrees Celsius.
A significant deactivating metabolic transformation of natural prostaglandins is enzymatic oxidation of the C-15 hydroxyl to the corresponding ketone. This is prevented, with retention of activity, by methylation to give the C-15 tertiary carbinol series.
This molecular feature is readily introduced at the stage of the Corey lactone (1) by reaction with methyl Grignard reagent or trimethylaluminium. The resulting mixture of tertiary carbinols (2) is transformed to oxytocic carboprost (3) by standard transformations, including sepoaration of diastereomers, so that the final product is the C-15 analogue. This diastereomer is reputably freeer of porstaglandin side effects than the C-15 (S) isomer.
- Bai, J; Sun, Q; Zhai, H (2014). "A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery.". Journal of Experimental and Therapeutic Medicine 7 (1): 46–50. doi:10.3892/etm.2013.1379. PMID 24348762.
- Hemabate [Package Insert]. New York, NY: Pharmacia and Upjohn Company; 2014.
- Ann. N.Y. Acad. Sci. 180, 76 (1971).
- Carboprost at the US National Library of Medicine Medical Subject Headings (MeSH)
- Indman P (2004). "Use of carboprost to facilitate hysteroscopic resection of submucous myomas". J Am Assoc Gynecol Laparosc 11 (1): 68–72. doi:10.1016/S1074-3804(05)60014-X. PMID 15104835.
- Vukelić J (2001). "Second trimester pregnancy termination in primigravidas by double application of dinoprostone gel and intramuscular administration of carboprost tromethamine". Med Pregl 54 (1–2): 11–6. PMID 11436877.
- Ippoliti C, Przepiorka D, Mehra R, Neumann J, Wood J, Claxton D, Gajewski J, Khouri I, van Besien K, Andersson B (1995). "Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation". Urology 46 (6): 811–5. doi:10.1016/S0090-4295(99)80349-5. PMID 7502421.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|